Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

54.100
-3.000-5.25%
Volume:2.92M
Turnover:157.82M
Market Cap:10.77B
PE:-38.23
High:57.500
Open:56.950
Low:52.750
Close:57.100
52wk High:97.500
52wk Low:44.720
Shares:199.00M
HK Float Shares:198.00M
Volume Ratio:1.17
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.415
ROE:-51.55%
ROA:-12.87%
PB:9.89
PE(LYR):-38.23
PS:43.17

Loading ...

Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of Lbl‑051 for Refractory Autoimmune Diseases

THOMSON REUTERS
·
Aug 04

Leads Biolabs’ partner Oblenio opens Phase Ia trial for trispecific T-cell engager LBL-051; company clarifies connected share-award transaction

Bulletin Express
·
Aug 04

Nanjing Leads Biolabs Clarifies Award Grant to Executive Director is Exempt Connected Transaction Under HK Rules

Reuters
·
Aug 04

Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Ind Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

THOMSON REUTERS
·
Aug 03

LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment

Stock News
·
Aug 03

LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total

Stock News
·
Aug 03

Nanjing Leads Biolabs Co - Lbl-024 Receives Ind Approval from Nmpa for Metastatic Colorectal Cancer

THOMSON REUTERS
·
Aug 03

Nanjing Leads Biolabs Says China Regulator Clears IND for Lbl-024 in Metastatic Colorectal Cancer

Reuters
·
Aug 03

Movement Alert|LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment

Market Focus
·
Jul 31

LEADS BIOLABS-B (09887) Records 346 Million Hong Kong Dollar Share Transfer, Representing 3.39% of Total Shares

Stock News
·
Jul 31

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Completes Patient Enrollment in Phase Ii Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors

THOMSON REUTERS
·
Jul 30

Leads Biolabs completes full enrollment of 70-patient Phase II trial for bispecific antibody LBL-024 in first-line advanced biliary tract cancer

Bulletin Express
·
Jul 30

Nanjing Leads Biolabs Completes Enrollment in Phase II Opamtistomig Trial for Advanced Biliary Tract Cancer

Reuters
·
Jul 30

LEADS BIOLABS-B (09887) Records a Major Securities Transfer Valued at HK$746 Million, Representing 7.10% of Total Shares, with 13.76 Million Shares Moved from China Securities Depository and Clearing Hong Kong

Stock News
·
Jul 30

Hong Kong Stocks Update: LEADS BIOLABS-B (09887) Drops Over 7% Further, Kpc Pharmaceuticals Plans to Sell HKD 132 Million Stake, Founder Voluntarily Extends Lock-Up Period

Stock News
·
Jul 28

Movement Alert|LEADS BIOLABS-B Falls 5.51% in Regular Trading, Lock-Up Expiry Triggers Selling Pressure as Kunming Pharma Exits Position

Market Focus
·
Jul 28

KPC Pharmaceuticals to Divest Stake in Nanjing Leads Biolabs

MT Newswires Live
·
Jul 27

Hong Kong Stock Market Midday Review: Hang Seng Index Rises 0.81% as Xiaomi Leads the Blue Chips with a 7% Gain

Stock News
·
Jul 27

New Forecasts: Here's What Analysts Think The Future Holds For Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Simply Wall St.
·
Jul 23

LEADS BIOLABS-B Shares Surge Over 11%, Marking a 30% Gain in Three Days on ESMO Research News

Stock News
·
Jul 15